Human immunodeficiency virus and liver disease: Conference proceedings†
Version of Record online: 22 OCT 2009
Copyright © 2009 American Association for the Study of Liver Diseases
Volume 51, Issue 3, pages 1046–1054, March 2010
How to Cite
Sherman, K. E., Soriano, V. and Chung, R. T. (2010), Human immunodeficiency virus and liver disease: Conference proceedings. Hepatology, 51: 1046–1054. doi: 10.1002/hep.23394
Potential conflict of interest: Unrestricted educational grants from pharmaceutical sponsors to support this meeting were provided by Roche, Gilead Sciences, Vertex Pharmaceuticals, Bristol-Meyers Squibb, Merck, Tibotec, and Valeant. Continuing Medical Education credit and content oversight were provided by the University of Wisconsin School of Medicine and Public Health. Dr. Sherman advises Astellas, Valeant, Vertex, Merck, and Anadys. He received grants from Schering-Plough, HGO, and GlasoSmithKline. He advises and received grants from Sciclone. Dr. Soriano is a consultant for, advises, and is on the speakers' bureau of Roche. He is a consultant for and advises Schering-Plough. He is also a consultant for, advises, is on the speakers' bureau of, and received grants from Gilead.
- Issue online: 2 MAR 2010
- Version of Record online: 22 OCT 2009
- Accepted manuscript online: 22 OCT 2009 12:00AM EST
- Manuscript Accepted: 13 OCT 2009
- Manuscript Received: 19 JUN 2009
- NIAID. Grant Number: Award Number R13 AI 071925
- 15GESIDA. Survival of HIV/HCV co-infected patients with compensated liver cirrhosis: effects of HCV therapy [Abstract]. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2009; Montreal, Canada. Abstract 106., , , , , , et al.; and
- 16Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005; 21: 743–752., , , , , , et al.
- 20HIV entry and replication in stellate cells promotes cellular activation and fibrogenesis: implications for hepatic fibrosis in HIV/HCV co-infection [Abstract]. In: 58th Annnual Meeting of the American Association for the Study of Liver Diseases; November 2–6, 2007; Boston, MA. Abstract LB3., , , , , , et al.
- 28Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007; 102: 2536–2540., , , .Direct Link:
- 37ACTG A5178 Study Team. Sustained long-term antiviral maintenance with pegylated interferon in HCV/HIV coinfected patients: early viral response and effect on fibrosis in treated and control subjects [Abstract]. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3–6, 2008; Boston, MA. Abstract 59., , , , , , et al; and